In addition, CAPN1 could promote AKT signaling and melanoma cell growth via degrading tumor suppressor NF1, and combination treatment of CAPN1 inhibitor and with MEKi trametinib could inhibit cell malignant phenotype more effectively compared to treatment with trametinib alone,34 which also indicated that CAPN1 can be a potential target for tumor treatment. Here, AKT1 is linked to melanoma.